187 related articles for article (PubMed ID: 34908176)
21. Statins for Graves' orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial.
Lanzolla G; Sabini E; Leo M; Menconi F; Rocchi R; Sframeli A; Piaggi P; Nardi M; Marcocci C; Marinò M
Lancet Diabetes Endocrinol; 2021 Nov; 9(11):733-742. PubMed ID: 34592164
[TBL] [Abstract][Full Text] [Related]
22. Monoclonal antibodies for the treatment of Graves' ophthalmopathy: A systematic review and meta-analysis.
Fatani WA; Hamdan DM; Taher NO; Alsharef JF; Aldubi RM; Alwagdani AM; Alhothali TN; Khan ZU
Saudi J Ophthalmol; 2023; 37(2):137-148. PubMed ID: 37492211
[TBL] [Abstract][Full Text] [Related]
23. Treatment of active corticosteroid-resistant graves' orbitopathy.
Pérez-Moreiras JV; Alvarez-López A; Gómez EC
Ophthalmic Plast Reconstr Surg; 2014; 30(2):162-7. PubMed ID: 24503568
[TBL] [Abstract][Full Text] [Related]
24. Utility of tocilizumab in autoimmune eye diseases.
Atienza-Mateo B; Prieto-Peña D; Vicente-Rabaneda EF; Blanco R; González-Gay MA; Castañeda S
Expert Opin Biol Ther; 2022 Jun; 22(6):789-799. PubMed ID: 35422184
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and Safety of intravenous monoclonal antibodies in patients with moderate-to-severe active Graves'ophthalmopathy: a systematic review and meta-analysis.
Hu Y; Chen J; Lin K; Yu X
Front Endocrinol (Lausanne); 2023; 14():1160936. PubMed ID: 37288301
[TBL] [Abstract][Full Text] [Related]
26. Optimization of the treatment of moderate to severe and active thyroid orbitopathy considering the recommendations of the European Group on Graves' Orbitopathy (EUGOGO) [Optymalizacja leczenia umiarkowanej do ciężkiej i aktywnej orbitopatii tarczycowej z uwzględnieniem zaleceń European Group on Graves' Orbitopathy (EUGOGO)].
Nowak M; Marek B; Kos-Kudła B; Siemińska L; Londzin-Olesik M; Głogowska-Szeląg J; Nowak W; Kajdaniuk D
Endokrynol Pol; 2022; 73(4):756-777. PubMed ID: 36059167
[TBL] [Abstract][Full Text] [Related]
27. TSH receptor specific monoclonal autoantibody K1-70
Furmaniak J; Sanders J; Sanders P; Li Y; Rees Smith B
Clin Endocrinol (Oxf); 2022 Jun; 96(6):878-887. PubMed ID: 35088429
[TBL] [Abstract][Full Text] [Related]
28. Serum concentrations of HGF and IL-8 in patients with active Graves' orbitopathy before and after methylprednisolone therapy.
Nowak M; Siemińska L; Karpe J; Marek B; Kos-Kudła B; Kajdaniuk D
J Endocrinol Invest; 2016 Jan; 39(1):63-72. PubMed ID: 26062519
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of mycophenolate mofetil in patients with active moderate-to-severe Graves' orbitopathy.
Ye X; Bo X; Hu X; Cui H; Lu B; Shao J; Wang J
Clin Endocrinol (Oxf); 2017 Feb; 86(2):247-255. PubMed ID: 27484048
[TBL] [Abstract][Full Text] [Related]
30. Sight-threatening Graves' orbitopathy: Twenty years' experience of a multidisciplinary thyroid-eye outpatient clinic.
Tramunt B; Imbert P; Grunenwald S; Boutault F; Caron P
Clin Endocrinol (Oxf); 2019 Jan; 90(1):208-213. PubMed ID: 30339291
[TBL] [Abstract][Full Text] [Related]
31. Relationship between longitudinal behaviour of some markers of eye autoimmunity and changes in ocular findings in patients with Graves' ophthalmopathy receiving corticosteroid therapy.
De Bellis A; Bizzarro A; Conte M; Coronella C; Solimeno S; Perrino S; Sansone D; Guaglione M; Wall JR; Bellastella A
Clin Endocrinol (Oxf); 2003 Sep; 59(3):388-95. PubMed ID: 12919164
[TBL] [Abstract][Full Text] [Related]
32. Efficacy Profile and Safety of Very Low-Dose Rituximab in Patients with Graves' Orbitopathy.
Vannucchi G; Campi I; Covelli D; Currò N; Lazzaroni E; Palomba A; Soranna D; Zambon A; Fugazzola L; Muller I; Guastella C; Salvi M
Thyroid; 2021 May; 31(5):821-828. PubMed ID: 33234032
[No Abstract] [Full Text] [Related]
33. Antithyroid drugs in Graves' hyperthyroidism: differences between "block and replace" and "titration" regimes in frequency of euthyroidism and Graves' orbitopathy during treatment.
Žarković M; Wiersinga W; Perros P; Bartalena L; Donati S; Okosieme O; Morris D; Fichter N; Lareida J; Daumerie C; Burlacu MC; Kahaly GJ; Pitz S; Beleslin B; Ćirić J; Ayvaz G; Konuk O; Törüner FB; Salvi M; Covelli D; Curro N; Hegedüs L; Brix T;
J Endocrinol Invest; 2021 Feb; 44(2):371-378. PubMed ID: 32524368
[TBL] [Abstract][Full Text] [Related]
34. Correlation between serum anti-TSH receptor autoantibodies (TRAbs) and the clinical feature of Graves' orbitopathy.
Nicolì F; Lanzolla G; Mantuano M; Ionni I; Mazzi B; Leo M; Sframeli A; Posarelli C; Maglionico MN; Figus M; Nardi M; Marcocci C; Marinò M
J Endocrinol Invest; 2021 Mar; 44(3):581-585. PubMed ID: 32648002
[TBL] [Abstract][Full Text] [Related]
35. Tocilizumab as first treatment option in optic neuropathy secondary to Graves' orbitopathy.
Pascual-Camps I; Molina-Pallete R; Bort-Martí MA; Todolí J; España-Gregori E
Orbit; 2018 Dec; 37(6):450-453. PubMed ID: 29420104
[TBL] [Abstract][Full Text] [Related]
36. Corticosteroids in Moderate-To-Severe Graves' Ophthalmopathy: Oral or Intravenous Therapy?
Penta L; Muzi G; Cofini M; Leonardi A; Lanciotti L; Esposito S
Int J Environ Res Public Health; 2019 Jan; 16(1):. PubMed ID: 30626069
[TBL] [Abstract][Full Text] [Related]
37. The effects of Rituximab on Graves'orbitopathy: A retrospective study of 14 patients.
Eid L; Coste-Verdier V; Longueville E; Ribeiro E; Nicolescu-Catargi B; Korobelnik JF
Eur J Ophthalmol; 2020 Sep; 30(5):1008-1013. PubMed ID: 31025590
[TBL] [Abstract][Full Text] [Related]
38. Clinical relevance of estimating circulating interleukin-17 and interleukin-23 during methylprednisolone therapy in Graves' orbitopathy: A preliminary study.
Kościuszko M; Popławska-Kita A; Pawłowski P; Lipińska D; Hryniewicka J; Jankowska D; Górska M; Krętowski A; Myśliwiec J
Adv Med Sci; 2021 Sep; 66(2):315-320. PubMed ID: 34256242
[TBL] [Abstract][Full Text] [Related]
39. Putative protective role of autoantibodies against the insulin-like growth factor-1 receptor in Graves' Disease: results of a pilot study.
Lanzolla G; Ricci D; Nicolì F; Sabini E; Sframeli A; Brancatella A; Mantuano M; Dottore GR; Bucci I; Figus M; Nardi M; Latrofa F; Marcocci C; Marinò M
J Endocrinol Invest; 2020 Dec; 43(12):1759-1768. PubMed ID: 32583374
[TBL] [Abstract][Full Text] [Related]
40. Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves' disease and Graves' orbitopathy.
Marinò M; Rotondo Dottore G; Ionni I; Lanzolla G; Sabini E; Ricci D; Sframeli A; Mazzi B; Menconi F; Latrofa F; Vitti P; Marcocci C; Chiovato L
J Endocrinol Invest; 2019 Apr; 42(4):471-480. PubMed ID: 30132285
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]